Nasdaq

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...
Business Insider

The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE™ (Buprenorphine Extended-Release) Injection in Patients with ...

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". SLOUGH, England and RICHMOND, Va., March 7, 2019 /PRNewswire/ -- Indivior ...
The Desert Sun

Integrity Treatment Partners Now Offers Monthly Sublocade and Vivitrol Injections for Opioid and Alcohol Addiction

Monthly injections work great. Patients come in once a month, get their shot, and can focus on the rest of their treatment.” — Samantha Callister, Executive Director Integrity Treatment Partners ...

‘Life-saving’ drug for people with opioid dependency to be pulled from Australia by end of year

Exclusive: Fears that US companies may withdraw more medicines as global markets react to policy changes by the Trump administration ...
Monthly Prescribing Reference

Updated Sublocade Label Includes Rapid Induction, Alternative Injection Sites

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.
Nasdaq

SUBLOCADE® Long-Term Safety Data Published in Journal of Clinical Psychopharmacology

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...